Why Summit Therapeutics Stock Is Trading 8% Higher Monday
Why Summit Therapeutics Stock Is Trading 8% Higher Monday
Summit Therapeutics, Inc. (NASDAQ:SMMT) stock is moving higher Monday following the company's announcement that it received marketing authorization in China for ivonescimab in combination with chemotherapy.
纳斯达克（NASDAQ）：康方生物（Akeso）赞助的第三期HARMONi-A临床试验数据表明，ivonescimab用于某些类型的晚期非小细胞肺癌的联合治疗的总有效率为50.6％，相较于仅接受化疗的人群为35.4％。该研究还表明，ivonescimab与化疗联合使用可将疾病进展的风险减少54％。 周一，峰峰药业（Summit Therapeutics）宣布，在中国获得ivonescimab联合化疗药物的上市授权，推动了该股票的上涨。
What Happened: Based on data from a Phase III HARMONi-A clinical trial, sponsored by Akeso, that showed promising results for treating certain cancers, China granted Summit the marketing authorization.
具体来说，根据由康方生物赞助的第三期HARMONi-A临床试验数据，该研究显示ivonescimab在治疗某些癌症方面有着良好的实验结果后，中国授予了Summit的上市授权。
Specifically, the clinical trial included patients with certain types of advanced non-small cell lung cancer. The overall response rate for the combined treatment was 50.6% compared to 35.4% for those only receiving chemotherapy.
该临床试验针对晚期非小细胞肺癌患者进行，应用联合治疗总体有效率比仅接受化疗的人群高出15.2%。
In addition, the study showed that ivonescimab in combination with chemotherapy led to a 54% reduction in the risk of disease progression compared to chemotherapy.
此外，该研究还表明，ivonescimab与化疗联合使用可将疾病进展的风险减少54％，相较于仅接受化疗的人群。
"We are excited to continue to develop ivonescimab with appropriate, accelerated pace and with the intent to make a significant difference for those patients who may benefit most from new, innovative therapies in lung cancer and other solid tumors," added Dr. Maky Zanganeh, CEO and president of Summit.
Summit的首席执行官兼总裁Maky Zanganeh博士表示：“我们很高兴能够以适当而加速的速度继续开发ivonescimab，目的是在肺癌和其他实体瘤治疗领域为那些最有可能受益于新型创新疗法的患者带来重要的不同。”
Separately, Summit announced that it accepted an unsolicited offer from an institutional investor to buy 22 million shares of its common stock at $9.00 each, raising $200 million in gross proceeds.
此外，峰峰药业还宣布，接受了一家机构投资者以每股9.00美元的价格购买其普通股2200万股的无意向性收购，募集了2亿美元的总收益。
The company intends to use the proceeds in part to continue the development of invonescimab. Summit also intends to use the funds as working capital and for general corporate purposes.
峰峰药业拟将募集的资金用于继续发展ivonescimab，同时还将用于营运资本和企业一般用途。
Related Link: Ionis Pharmaceuticals Reveals Late-Stage Donidalorsen Data, Analyst Says Results Show Competitive Hereditary Angioedema Profile
相关链接：爱文思控股发布晚期Donidalorsen数据，分析师表示结果显示竞争性的遗传性血管性水肿概况
SMMT Price Action: Summit Therapeutics shares are trading 8.12% higher at $9.39, according to data from Benzinga Pro.
根据Benzinga Pro的数据，峰峰药业的股票价格上涨8.12％至9.39美元。
Image: 3139127 from Pixabay.
图片来源：Pixabay的3139127。